HER2 amplification (2–5%) and RAS–MAPK pathway mutations (e.g., KRAS G12D, BRAF V600E) further drive resistance, while PI3K pathway activation via PIK3CA mutations or PTEN loss promotes tumor survival. This evidence concerns the gene KRAS and neoplasm.